Bendamustine is generally well tolerated. The most common serious (grade 3 or 4) adverse events are hematologic in nature. Gastrointestinal events are also commonly observed but are usually mild ...

There is also a two-drug combination of rituximab plus a newer chemotherapy drug, bendamustine (Belrapzo, Bendeka, Treanda). Some younger people with mantle cell lymphoma will get one or more high ...

WILMINGTON, Del. - The U.S. Food and Drug Administration (FDA) has granted approval to AstraZeneca (NASDAQ:AZN)'s CALQUENCE® (acalabrutinib) in combination with bendamustine and rituximab for the ...

Concurrently, AstraZeneca's Calquence (acalabrutinib) in combination with bendamustine and rituximab was recommended for approval in the European Union for adult patients with previously untreated ...

EMA committee recommends approval of AstraZeneca’s Calquence plus chemoimmunotherapy to treat adult patients with mantle cell lymphoma: Cambridge, UK Tuesday, April 1, 2025, 17: ...

People who are older or have underlying health issues may not tolerate such powerful chemo drugs. In this case, doctors may start with something milder, such as bendamustine (Belrapzo, Bendeka ...

That approval also included first-line use of the drug for eligible patients unsuitable for chemo-immunotherapy, typically carried out with bendamustine plus rituximab, or dexamethasone plus ...

AstraZeneca’s Calquence (acalabrutinib) in combination with bendamustine and rituximab has been recommended for approval in the European Union (EU) for the treatment of adult patients with previously ...

[17] Bendamustine should not be used in patients with severe renal impairment (creatinine clearance of <40 mL/min), moderate hepatic impairment (aspartate transaminase or alanine transaminase ...

The U.S. Food and Drug Administration (FDA) on Monday approved AstraZeneca Plc's (NASDAQ:AZN) Imfinzi (durvalumab) in ...